Among vasculogenic ED patients, traditional ED treatments such as selective PDE5 inhibitors, which act on the penile musculature via the NO system, often fail to elicit long-term therapeutic outcomes in subjects with severe cardiovascular and metabolic disease
Now, in regards to the failed sphincter function after different NSAIDs, and later, to the improved sphincter function and smooth muscle function when BPC 157 was given, BPC 157, as a particular anti-ulcer pentadecapeptide, LD1 could be not achieved, effective alone without carrier (1-7) may be a suitable peptide candidate to additionally rescue such extended NSAIDs toxicity (1-14)
In the research peptide market, where vendor collapses and quality concerns have eroded buyer trust, an independently verified 5-star rating is the strongest form of social proof available
Lancet 1991;338:131-7 American Academy of Pediatrics (AAP) Committee on Drugs